Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004

Barton, D. L., Pugh, S. L., Ganz, P. A., Plaxe, S. C., Koontz, B. F., Carter, J., Greyz-Yusupov, N., Page, S. J., Rowland, K. M., Balcueva, E. P., Nabeel, S., Basil, J. B., Hill, M. L., Muller, C. Y., Bell, M. C., Deshmukh, S., & Kachnic, L. A. (2022). Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004. Journal of Clinical Oncology, 40(4), 324–334. https://doi.org/10.1200/jco.21.01473
Authors:
Debra L. Barton
Stephanie L. Pugh
Snehal Deshmukh
Patricia A. Ganz
Steven C. Plaxe
Bridget F. Koontz
Jeanne Carter
Natalya Greyz-Yusupov
Seth J. Page
Kendrith M. Rowland
Ernie P. Balcueva
Sobia Nabeel
Jack B. Basil
Matthew L. Hill
Carolyn Y. Muller
Maria C. Bell
Lisa A. Kachnic
Affiliated Authors:
Lisa A. Kachnic
Columbia Affiliation:
Subjects:
Breast Neoplasms (MeSH)
Bupropion (MeSH)
Cancer Survivors (MeSH)
Dopamine Uptake Inhibitors (MeSH)
Genital Neoplasms, Female (MeSH)
Sexual Behavior (MeSH)
Sexual Dysfunctions, Psychological (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1200/JCO.21.01473
PMID:
34882500
DOI:
10.1200/JCO.21.01473
Journal:
Journal of Clinical Oncology
Publication Date:
Data Source:
Web of Science
Source Link:
View Web of Science Record
View PubMed Record

Record Created: